New insights in therapeutic options against difficult-to-threat Pseudomonas aeruginosa (DTR-PA): in vitro activity of aztreonam in combination with avibactam, relebactam and in double ?-lactams combinations with ceftazidime/avibactam and imipenem/relebactam.